DOP2012000044A - Anticuerpos contra el extodominio de erbb3 y usos de los mismos - Google Patents

Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Info

Publication number
DOP2012000044A
DOP2012000044A DO2012000044A DO2012000044A DOP2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A
Authority
DO
Dominican Republic
Prior art keywords
erbb3
same
antibodies
receiver
antigen
Prior art date
Application number
DO2012000044A
Other languages
English (en)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of DOP2012000044A publication Critical patent/DOP2012000044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UNA NUEVA CLASE DE ANTICUERPOS Y FRAGMENTOS DE UNION A ANTIGENO DE LOS MISMOS QUE SE UNEN AL DOMICILIO EXTRACELULAR DEL RECEPTOR ERBB3 E INHIBEN DIVERSAS FUNCIONES DE ERBB3. POR EJEMPLO, LOS ANTICUERPOS Y FRAGMENTOS DE UNION A ANTIGENO DESCRITOS EN LA PRESENTE SON CAPACES DE UNIRSE AL RECEPTOR DESIGNADO ERBB3 E INHIBIR LA FOSFORILACION MADIADA DE POR LIGANDO SIMILAR A EGF DEL RECEPTOR. DICHOS ANTICUERPOSY FRAGMENTOS DE UNION A ANTIGENO DE LOS MISMOS TIENE LA CARACTERISTICA UTIL DE INHIBIR LA PROLIFERACION DE CELULAS CANCERIGENAS QUE EXPRESAN ERBB3.
DO2012000044A 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos DOP2012000044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
DOP2012000044A true DOP2012000044A (es) 2012-06-30

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000044A DOP2012000044A (es) 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Country Status (21)

Country Link
EP (1) EP2467164A2 (es)
JP (1) JP5752687B2 (es)
KR (1) KR20120059568A (es)
CN (1) CN103002912A (es)
AU (1) AU2010284018C1 (es)
BR (1) BR112012003809A2 (es)
CA (1) CA2771744A1 (es)
CR (1) CR20120108A (es)
DO (1) DOP2012000044A (es)
EA (1) EA201200195A1 (es)
EC (1) ECSP12011740A (es)
IL (1) IL218097A0 (es)
IN (1) IN2012DN01518A (es)
MA (1) MA33582B1 (es)
MX (1) MX336091B (es)
NI (1) NI201200027A (es)
PE (1) PE20121585A1 (es)
SG (1) SG178509A1 (es)
TN (1) TN2012000057A1 (es)
WO (1) WO2011022727A2 (es)
ZA (1) ZA201201195B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
JP5931736B2 (ja) 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Ｈｅｒ−３関連疾患を治療または予防するための物質および方法
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
DK2699602T3 (en) 2011-04-19 2017-06-06 Merrimack Pharmaceuticals Inc BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
EP2722343A4 (en) * 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-ERBB3 ANTIBODIES
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
ES2694153T3 (es) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2788377B1 (en) 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
MA49846A (fr) 2017-08-09 2020-06-17 Merus Nv Anticorps qui se lient à l'egfr et à cmet
WO2019028555A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan HER3 BINDING AGENTS AND USES THEREOF
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania

Also Published As

Publication number Publication date
IN2012DN01518A (es) 2015-06-05
KR20120059568A (ko) 2012-06-08
ECSP12011740A (es) 2013-02-28
AU2010284018C1 (en) 2015-10-15
SG178509A1 (en) 2012-04-27
MX336091B (es) 2016-01-08
MX2012002172A (es) 2012-05-29
EP2467164A2 (en) 2012-06-27
WO2011022727A2 (en) 2011-02-24
AU2010284018A1 (en) 2012-03-22
JP5752687B2 (ja) 2015-07-22
PE20121585A1 (es) 2012-11-29
AU2010284018B2 (en) 2014-06-05
IL218097A0 (en) 2012-04-30
NI201200027A (es) 2013-01-29
MA33582B1 (fr) 2012-09-01
WO2011022727A3 (en) 2013-06-27
CA2771744A1 (en) 2011-02-24
BR112012003809A2 (pt) 2019-09-24
CN103002912A (zh) 2013-03-27
EA201200195A1 (ru) 2012-12-28
JP2013506622A (ja) 2013-02-28
ZA201201195B (en) 2015-07-29
CR20120108A (es) 2012-06-05
TN2012000057A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
DOP2012000044A (es) Anticuerpos contra el extodominio de erbb3 y usos de los mismos
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
CL2018002380A1 (es) Divisional de la solicitud 2433-2012 por anticuerpos reactivos con b7-h3, fragmentos inmunológicamente activos de los mismos y sus usos.
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP099637A (es) Anticuerpos contra el erbb3 y los usos de los mismos
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
BR112018009129A2 (pt) receptores de antígeno quimérico que visam her2
DOP2015000269A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
UY37005A (es) Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
MX2017003596A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
UY37026A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
UY34601A (es) ?mezclas fungicidas de pirazol?.
TR201906047T4 (tr) Göz dokusunun çapraz bağlanması.
EA201270465A1 (ru) Новейшие модуляторы
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CY1119154T1 (el) Anti-vla-4 αντισωματα
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
TR201905272T4 (tr) İmmünojenik bileşim.
TR201911084T4 (tr) İnsan yapımı camlı fiberler.
MX2018004289A (es) Receptores de antigenos quimericos dirigidos a psca.
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CL2017001445A1 (es) Fibras de polipropileno mejoradas, métodos para producirlas y sus usos para la producción de productos de fibrocemento.